- Home
- / Hubro Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Hubro Therapeutics financials data including stock price, CreditSafe score, income statement, and balance sheet.
Revenue
KR53.6 K
FY, 2021
CreditSafe Score
?
Score changed on Jul 19, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| NOK | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|
| Revenue | 50.4K | 53.6K | |
| Gross profit | 50.4K | 53.6K | |
| Gross profit margin, % | 100.0% | 100.0% | |
| General and administrative expense | 1.4M | 2.9M | 1.6M |
| Operating expense total | 2.9M | 7.6M | 7.7M |
| EBIT | (2.1M) | (7.6M) | (7.7M) |
| EBIT margin, % | -4251.8% | -14288.3% | |
| Interest income | 19.7K | 202.6K | |
| Interest expense | 4.5K | ||
| Pre tax profit | (2.1M) | (7.5M) | (7.5M) |
| Income tax expense | (577.9K) | 577.9K | |
| Net Income | (1.6M) | (8.1M) | (7.5M) |